Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6799477 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: Healthy Volunteers | EXPERIMENTAL | - |
| Part 2: Patients with T2D, Group A | EXPERIMENTAL | Low dose daily oral administration of RO6799477 |
| Part 2: Patients with T2D, Group B | EXPERIMENTAL | High dose daily oral administration of RO6799477 |
| Single oral dose group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo daily oral administration |
| RO6799477 | DRUG | Daily oral administration of RO6799477 |
Inclusion Criteria: Part 1 Inclusion criteria: * Right-handed male volunteers * Aged 18-45 years, inclusive * Healthy participants, as determined by screening assessments and Principal Investigator's judgment * Healthy status is defined by the absence of evidence of any active or chronic disease f...
RO6799477 is an investigational small molecule being studied for use in healthy volunteers and in patients with Type 2 Diabetes. It is being developed by Roche Holding AG and is currently in Phase 1 clinical development.
RO6799477 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule currently in Phase 1 clinical trials.
RO6799477 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are being conducted to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
RO6799477 has been studied in two completed Phase 1 clinical trials: NCT01893437, which enrolled 27 healthy volunteers in the Netherlands, and NCT02164266, which enrolled 40 participants including healthy volunteers and patients with Type 2 Diabetes. Both trials were completed.
No alternative names for RO6799477 have been disclosed. The drug is identified solely by its code name RO6799477 in clinical trial records.